"Integrating Biomarkers and Hemodynamics for 1-Year Mortality Risk Stratification in Transcatheter Tricuspid Intervention"

Figures

• 

  Figure 1. Study flow chart. Flow diagram showing patient screening, inclusion, intervention type, and follow-up to 12 months. EVOQUE System and PASCAL System (Edwards Lifesciences, Irvine, CA); TriClip T-TEER System (Abbott, Santa Clara, CA); TricValve System (P&F Products & Features, Vienna, Austria), T-TEER, transcatheter edge-to-edge repair.

• 

  Figure 2. (A) Predictive value for mortality: growth differentiation factor-15 (GDF-15) and soluble urokinase plasminogen activator receptor (suPAR) vs N-terminal pro-B-type natriuretic peptide (NT-proBNP). Receiver operating characteristic curves comparing biomarker performance for 1-year all-cause mortality. (B) Prognostic performance of GDF-15 when combined with right arterial pressure obtained from pre-interventional right heart catheterization (RAP). Receiver operating characteristic curves for biomarker prediction of 1-year all-cause mortality. AUC, area under the curve; CI, confidence interval; NT-proBNP, N-terminal pro-B-type natriuretic peptide; suPAR, soluble urokinase plasminogen activator receptor.

• 

  Figure 3. (A) Kaplan–Meier curve stratified by growth differentiation factor-15 (GDF-15). Survival curves for 1-year all-cause mortality according to GDF-15 threshold (≥ 2400 pg/mL vs < 2400 pg/mL). (B) Kaplan–Meier curve stratified by soluble urokinase plasminogen activator receptor (suPAR). Survival curves for 1-year all-cause mortality according to suPAR threshold (≥ 3350 ng/mL vs < 3350 ng/mL).